HomeABBV • NYSE
add
AbbVie Inc
Previous close
$177.06
Day range
$176.67 - $181.65
Year range
$137.65 - $207.32
Market cap
319.90B USD
Avg Volume
7.23M
P/E ratio
63.20
Dividend yield
3.62%
Primary exchange
NYSE
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 14.46B | 3.83% |
Operating expense | 6.07B | 21.67% |
Net income | 1.56B | -12.20% |
Net profit margin | 10.80 | -15.43% |
Earnings per share | 3.00 | 1.69% |
EBITDA | 6.26B | -8.02% |
Effective tax rate | 24.95% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 7.28B | -45.18% |
Total assets | 143.42B | 5.29% |
Total liabilities | 137.35B | 10.68% |
Total equity | 6.07B | — |
Shares outstanding | 1.77B | — |
Price to book | 51.92 | — |
Return on assets | 7.33% | — |
Return on capital | 13.48% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 1.56B | -12.20% |
Cash from operations | 5.45B | -28.08% |
Cash from investing | -8.26B | -2,137.40% |
Cash from financing | -3.07B | -15.45% |
Net change in cash | -5.87B | -229.70% |
Free cash flow | 5.50B | -26.01% |
About
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira, administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It developed Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases. Its other major products include Botox, Imbruvica to treat cancer, Rinvoq to treat arthritis, Venclexta to treat leukemia and lymphoma, Vraylar to treat schizophrenia and bipolar disorder, and Mavyret to treat Hepatitis C. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.
In 2023, Humira began facing competition from a biosimilar developed by Amgen. Wikipedia
Founded
Jan 1, 2013
Headquarters
Website
Employees
50,000
